MARKET

NLNK

NLNK

NewLink Genetics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.180
+0.010
+0.85%
Closed 16:00 10/14 EDT
OPEN
1.170
PREV CLOSE
1.170
HIGH
1.230
LOW
1.160
VOLUME
89.18K
TURNOVER
--
52 WEEK HIGH
2.480
52 WEEK LOW
1.130
MARKET CAP
44.03M
P/E (TTM)
-1.1525
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of NLNK and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

NLNK News

  • The Daily Biotech Pulse: IPOs, Puma's Breast Cancer Drug Gets Label Expansion, Buyout Offer For Organovo
  • Benzinga.10/03 11:34
  • The Daily Biotech Pulse: J&J Settles Ohio Opioid Lawsuit, Teligent Explores Options For Certain Assets, Novartis Reports Cosentyx Data
  • Benzinga.10/02 12:17
  • The Daily Biotech Pulse: J&J Settles Ohio Opioid Lawsuit, Teligent Explores Options For Certain Assets, Novartis Reports Cosentyx Data
  • Benzinga.10/02 11:17
  • 52 Biggest Movers From Yesterday
  • Benzinga.10/02 08:22

More

Industry

Biotechnology & Medical Research
+0.42%
Pharmaceuticals & Medical Research
+0.09%

Hot Stocks

Name
Price
%Change

About NLNK

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company's portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute Cellular Immunotherapy technology, which is designed to stimulate the human immune system to attack cancer cells. Its additional HyperAcute Cellular Immunotherapy product candidates in clinical development include tergenpumatucel-L and dorgenmeltucel-L for patients with advanced lung cancer and melanoma, respectively. Additionally, it has two small-molecule product candidates in clinical development: GDC-0919 and indoximod. These product candidates are indoleamine-2, 3-dioxygenase (IDO) pathway inhibitors and focus on breaking the immune system's tolerance to cancer.
More

Webull offers NewLink Genetics Corp (NLNK) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.